Bli medlem
Bli medlem

Du är här

2019-03-15

Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic announces partnership with Onkos Surg...

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company
Promimic
announces a new partnership with the U.S company Onkos Surgical® to
commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies
in Limb Salvage Surgery.

Promimic develops and markets products within nano-materials for innovative
surface treatments and has developed the HA nanoSurface that is clinically
proven to speed up and improve the anchoring of implants in bone. The
innovative technology is already licensed to several dental implant
companies. The partnership with Onkos Surgical®, a U.S company addressing the
clinical challenges associated with tumor surgery, represents an important
step into the orthopaedic space.

The partnership will focus on combining Promimic's HA nanoSurface Technology
with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to
aseptic loosening remains one of the key challenges associated with limb
salvage surgery. With HA nanoSurface, Onkos Surgical® aims to develop
implants with a porous coated ingrowth structure and thin layered HA.

"We are happy to see that Onkos Surgical acknowledges the potential in the
highly advanced technology that our portfolio company Promimic offers. This
further strengthens Promimic's position as a value creating partner for high
profiled orthopedic implant companies", said Viktor Drvota, CEO of Karolinska
Development.

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global
network.

For more information, please visitwww.karolinskadevelopment.com

KD Pressrelease Promimic March 2019
http://hugin.info/143071/R/2238677/882244.pdf

---------------------------------------
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.